FDG-PET predicts survival in recurrent high-grade gliomas treated with bevacizumab and irinotecan.
Colavolpe C, Chinot O, Metellus P, Mancini J, Barrie M, Bequet-Boucard C, Tabouret E, Mundler O, Figarella-Branger D, Guedj E. Neuro Oncol. 2012 May; 14(5):649-57. Epub 2012 Feb 29.